How effective is postoperative radiotherapy (RT) for ductal carcinoma in situ (DCIS) of the breast?
No information about short-term toxicity from radiotherapy or quality of life data was reported. Clinicians therefore need to ensure that comprehensive information relating to potential side effects is made available to women undergoing this treatment.
The addition of RT following BCS was first shown to reduce the risk of ipsilateral recurrence in the treatment of invasive breast cancer. DCIS is a pre-invasive lesion. Recurrence of ipsilateral disease following BCS can be either DCIS or invasive breast cancer. Randomised controlled trials (RCTs) have shown that RT can reduce the risk of recurrence, but assessment of potential long-term complications from the addition of RT following BCS for DCIS has not been reported for women participating in RCTs.